Numerous studies have found that in the U.S., minorities such as African Americans, Hispanics and Native Americans are often underrepresented in clinical trials. Regulatory agencies and various organizations are making an effort to address this issue.

A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.

Cancer drug study patients tend to be younger than most people with the disease in the general population.